GLPwatch

Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.

J Med Case Rep · 2014

Last updated 2026-05-28

A 38-year-old woman with severe obesity and type 2 diabetes took a GLP-1 receptor agonist (along with metformin and diet changes) for 14 months before planned weight-loss surgery. Her blood sugar control improved (hemoglobin A1c dropped from 7.4% to 5.5%), and she lost 21.2 kg (about 47 pounds) during that time.

AI summary of the abstract below.

JournalJ Med Case Rep, 2014
Citations1
Relative citation ratio0.06
NIH percentile5
Molecules
Conditions studied Type 2 Diabetes, Obesity

Abstract

INTRODUCTION: Glucagon-like peptide-1 receptor agonists, a new class of anti-diabetic drugs, are widely used in the treatment of type 2 diabetes. However, the effect of glucagon-like peptide-1 receptor agonists on the treatment of preoperative weight loss in obese type 2 diabetic patients has not been reported. CASE PRESENTATION: A 38-year-old Taiwanese woman presented to our hospital with morbid obesity and type 2 diabetes mellitus. Bariatric surgery was recommended by a general surgery specialist. Weight loss before surgery was recommended to reduce the frequency of surgical complications. In addition to diet control with lifestyle modifications, pharmacological treatment with metformin and glucagon-like peptide-1 receptor agonists was administered. Fourteen months of treatment reduced her hemoglobin A1c level from 7.4 to 5.5% and reduced her body weight by 21.2 kg. CONCLUSIONS: One year of diet control with lifestyle modifications and pharmacological treatment with glucagon-like peptide-1 receptor agonists and metformin markedly decreased hemoglobin A1c levels and resulted in effective and substantial weight loss in a morbidly obese patient with dysregulated diabetes during the preoperative period.

Verbatim abstract via PubMed 25213589 ↗